Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure. This effect happened through direct action on the heart muscle and blood vessels, despite resulting in no significant weight loss, according to preliminary research presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions (BCVS 2025). The meeting, held in Baltimore, July 23–26, 2025, offers the latest research on innovations and discovery in cardiovascular science.
This article was originally published on MedicalXpress.com
